Patents Assigned to I-MAB BIOPHARMA US LIMITED
-
Patent number: 11401331Abstract: Provided are fusion molecule having a PD-L1 inhibitor fused to a human IL-7 protein or fragment thereof through a peptide linker. The disclosed fusion molecules exhibited synergistic anti-tumor effects.Type: GrantFiled: January 25, 2019Date of Patent: August 2, 2022Assignee: I-Mab Biopharma US LimitedInventors: Lei Fang, Feifei Cui, Haijuan Gu, Zhengyi Wang, Bingshi Guo, Jingwu Zang
-
Patent number: 11261259Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.Type: GrantFiled: August 12, 2020Date of Patent: March 1, 2022Assignees: I-Mab Biopharma US Limited, ABL Bio Inc.Inventors: Wenqing Jiang, Lei Fang, Zhengyi Wang, Bingshi Guo, Eunyoung Park, Eunsil Sung, Byungje Sung
-
Patent number: 11220546Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 116, a VH CDR3 of SEQ ID NO: 117, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.Type: GrantFiled: March 29, 2019Date of Patent: January 11, 2022Assignee: I-Mab Biopharma US LimitedInventors: Lei Fang, Yongqiang Wang, Zhengyi Wang, Bingshi Guo, Jingwu Zang
-
Patent number: 11208486Abstract: Provided are full human anti-PD-L1 antibodies or fragments thereof. In various examples, the antibodies or fragments thereof include a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3 which are selected from sequence groups of SEQ ID NO: 35-42, SEQ ID NO: 43-51, SEQ ID NO: 52-66, SEQ ID NO: 67-79, SEQ ID NO:80-88 and SEQ ID NO: 89-102, respectively, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.Type: GrantFiled: April 26, 2020Date of Patent: December 28, 2021Assignee: I-Mab Biopharma US LimitedInventors: Lei Fang, Yuanyuan Yang, Zhengyi Wang, Bingshi Guo, Feifei Cui
-
Publication number: 20210269522Abstract: Provided are pharmaceutical compositions each comprising a glycosylation agent, an antibody that binds to human CD47, and a pharmaceutically acceptable carrier. Also provided are novel CD47 antibodies that bind to human CD47, wherein the antibodies bind to at least one epitope that is at one of the glycosylation sites of the CD47 protein of red blood cells (e. g, at least a glycosylation site near the epitope residues Gln31 and Thr34 in CD47).Type: ApplicationFiled: October 31, 2019Publication date: September 2, 2021Applicant: I-Mab Biopharma US LimitedInventors: Zhengyi Wang, Wei Cao, Lei Fang, Bingshi Guo
-
Patent number: 11059897Abstract: Provided are antibodies or fragments thereof having binding specificity to the human interferon alpha and beta receptor subunit 1 (IFNAR1) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as provided, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.Type: GrantFiled: September 18, 2019Date of Patent: July 13, 2021Assignee: I-Mab Biopharma US LimitedInventors: Wei Cao, Weili Xu
-
Patent number: 11034771Abstract: Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific antibodies are effective in treating cancer.Type: GrantFiled: July 25, 2019Date of Patent: June 15, 2021Assignee: I-Mab Biopharma US LimitedInventors: Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang, Qiumei Yang
-
Patent number: 11028164Abstract: Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL 13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.Type: GrantFiled: September 18, 2019Date of Patent: June 8, 2021Assignee: I-Mab Biopharma US LimitedInventors: Haijuan Gu, Qiumei Yang
-
Patent number: 10973853Abstract: The present disclosure provides antibodies and fragments thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.Type: GrantFiled: February 11, 2019Date of Patent: April 13, 2021Assignee: I-Mab Biopharma US LimitedInventors: Feifei Cui, Lei Fang, Bingshi Guo, Zhengyi Wang, Jingwu Zang
-
Publication number: 20210054093Abstract: The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.Type: ApplicationFiled: August 10, 2020Publication date: February 25, 2021Applicant: I-Mab Biopharma US LimitedInventors: Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang
-
Publication number: 20200407441Abstract: The present invention provides fusion proteins containing cytokines and novel CD47 antibodies or immunologically active fragments thereof, as well as pharmaceutical compositions containing such fusion proteins that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation. These fused proteins have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination.Type: ApplicationFiled: April 30, 2019Publication date: December 31, 2020Applicant: I-Mab Biopharma US LimitedInventors: Zhengyi Wang, Wei Cao, Lei Fang, Bingshi Guo
-
Publication number: 20200377611Abstract: The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.Type: ApplicationFiled: August 10, 2020Publication date: December 3, 2020Applicant: I-Mab Biopharma US LimitedInventors: Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang
-
Patent number: 10723799Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.Type: GrantFiled: August 9, 2018Date of Patent: July 28, 2020Assignee: I-Mab Biopharma US LimitedInventors: Lei Fang, Zhengyi Wang, Bingshi Guo, Jingwu Zang
-
Patent number: 10584169Abstract: Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.Type: GrantFiled: January 23, 2018Date of Patent: March 10, 2020Assignee: I-MAB BIOPHARMA US LIMITEDInventors: Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang